- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05256290
Studie av BDTX-1535, hos deltakere med glioblastom eller ikke-småcellet lungekreft
En fase 1-studie for å vurdere BDTX-1535, en oral EGFR-hemmer, hos deltakere med glioblastom eller ikke-småcellet lungekreft
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.
Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
Studieoversikt
Status
Forhold
- Ikke-småcellet lungekreft
- NSCLC
- Metastatisk lungekreft
- Metastatisk lunge ikke-småcellet karsinom
- EGF-R positiv ikke-småcellet lungekreft
- Avansert lungekarsinom
- EGFR-TKI resistent mutasjon
- Avansert ikke-småcellet plateepitel lungekreft
- Epidermal vekstfaktorreseptor C797S
- Epidermal vekstfaktorreseptor G719X
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: BDTX Clinical Trial Navigation Service
- Telefonnummer: (866) 955-4397
- E-post: blackdiamondtx@careboxhealth.com
Studiesteder
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Rekruttering
- BC Cancer Vancouver
-
Ta kontakt med:
- Vishaldeep Sidhu
- Telefonnummer: 236-994-8251
- E-post: ClinicalTrialsHelp@bccancer.bc.ca
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X5
- Rekruttering
- The Princess Margaret Cancer Centre
-
Ta kontakt med:
- Tuhina Paul
- Telefonnummer: 416-946-4501 x 7890
- E-post: Tuhina.Paul@uhn.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294
- Rekruttering
- University of Alabama
-
Ta kontakt med:
- Anna Wilbanks
- Telefonnummer: 205-934-6454
- E-post: annaburton@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, Forente stater, 85234
- Rekruttering
- Banner MD Anderson Cancer Center
-
Ta kontakt med:
- Brandi Luzania
- Telefonnummer: 480-256-5488
- E-post: Brandi.Luzania@bannerhealth.com
-
-
California
-
Irvine, California, Forente stater, 92618
- Rekruttering
- City of Hope Orange County Lennar Foundation Cancer Center
-
Ta kontakt med:
- Telefonnummer: 626-218-1133
-
Ta kontakt med:
- Diana Patterson
- Telefonnummer: 949-671-4763
-
Los Angeles, California, Forente stater, 90048
- Rekruttering
- Cedars Sinai Medical Center
-
Ta kontakt med:
- Garret Crook
- Telefonnummer: 424-314-0745
- E-post: Garrett.Crook@cshs.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20016
- Rekruttering
- Sibley Memorial Hospital Johns Hopkins Medicine
-
Ta kontakt med:
- Judith Lawrence
- Telefonnummer: 202-660-6500
- E-post: sibleyoncresreferral@live.johnshopkins.edu
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32224
- Rekruttering
- Mayo Clinic- Jacksonville
-
Ta kontakt med:
- Yanyan Lou
- Telefonnummer: 855-776-0015
-
Miami, Florida, Forente stater, 33176
- Rekruttering
- Miami Cancer Institute - Baptist Health South Florida
-
Ta kontakt med:
- Xiaoou Pan
- Telefonnummer: 785-594-7856
- E-post: Xiaoou.pan@baptisthealth.net
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96813
- Rekruttering
- UHP- University of Hawaii Cancer Center
-
Ta kontakt med:
- Evan Wu, MD
- Telefonnummer: 808-586-3010
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
Ta kontakt med:
- E-post: clinicaltrials@northwestern.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Dana-Farber Cancer Institute
-
Ta kontakt med:
- Dawn Bissessar
- Telefonnummer: 617-632-5119
- E-post: dawn_bissessar@dfci.harvard.edu
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic- Rochester
-
Ta kontakt med:
- Anastasios Dimou, MD
- Telefonnummer: 855-776-0015
-
-
New York
-
The Bronx, New York, Forente stater, 10461
- Rekruttering
- Montefiore Medical Center
-
Ta kontakt med:
- Balazs Halmos, MD
- Telefonnummer: 718-405-8404
- E-post: bahalmos@montefiore.org
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- Rekruttering
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
Ta kontakt med:
- Jennifer Ruth
- E-post: ruthj2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tennessee Oncology
-
Ta kontakt med:
- Melissa Johnson, MD
- Telefonnummer: 615-320-5090
- E-post: melissa.johnson@scri.com
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- Inova Schar Cancer Institute
-
Ta kontakt med:
- Stephanie Van Bebber
- Telefonnummer: 571-472-0213
- E-post: Stephanie.VanBebber@inova.org
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- Next Oncology
-
Ta kontakt med:
- Rebecca Fisher
- E-post: rfisher@nextoncology.com
-
-
Washington
-
Seattle, Washington, Forente stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center/University of Washington
-
Ta kontakt med:
- Sam Woodman
- Telefonnummer: 206-606-6346
- E-post: swoodman@fredhutch.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Phase 2 Eligibility:
Key Inclusion Criteria Required for locally advanced or metastatic NSCLC:
-
Measurable disease by RECIST 1.1 criteria.
-
Adequate bone marrow or organ function.
-
Life expectancy of ≥ 3 months.
-
Sufficient performance status.
-
Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases.
-
Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort):
- Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutation (eg, G719X) following up to 2 lines of therapy with only 1 prior EGFR TKI regimen (third-generation preferred; other approved EGFR TKI acceptable).
- Cohort 2 (Acquired resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third generation EGFR TKI (eg, osimertinib).
- Cohort 3 and 4 (First-line non-classical driver cohort): Treatment-naïve advanced/metastatic NSCLC with a non-classical driver EGFR mutations (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion.
-
Identification of one (or more) of the following EGFR mutations by Next Generation Sequencing (NGS) as determined by a local assay performed in a validated laboratory in the absence of other known resistance mutations (eg, T790M, MET):
- Non-classical driver EGFR mutations (eg, L861R, S768I, G719X).
- EGFR acquired resistance mutation (eg, C797S) to a 3rd generation EGFR TKI.
- For Phase 2, dose expansion, patients in Cohort 1 who received 3rd generation EGFR TKI (eg, osimertinib), the NGS report within 6 months prior to the start of Screening is acceptable. For patients in Cohort 2, the NGS report must be from the last disease progression on the immediate prior therapy. For patients in Cohort 3 and 4, the NGS report must be at the time of diagnosis.
Key Exclusion Criteria:
- Known resistant mutations in tumor tissue or by liquid biopsy (eg, T790M, MET).
- Received more than 1 EGFR TKI therapy (ie, erlotinib or gefitinib) for the treatment of metastatic or recurrent EGFR NSCLC.
- Any history of interstitial lung disease related to EGFR TKI use.
- Symptomatic or radiographic leptomeningeal disease.
- Symptomatic brain metastases or spinal cord compression requiring urgent clinical intervention.
- Unresolved toxicity from prior therapy.
- Significant cardiovascular disease.
- Major surgery within 4 weeks of study entry or planned during study.
- Ongoing or recent anticancer therapy or radiation therapy.
- Evidence of malignancy (other than study-specific malignancies) requiring active therapy within the next 2 years.
- Active hepatitis B or C infection and/or known human immunodeficiency virus (HIV) carrier.
- Poorly controlled gastrointestinal disorders.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)
|
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navn:
|
|
Eksperimentell: Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)
Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable) |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navn:
|
|
Eksperimentell: Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed)
Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib) |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navn:
|
|
Eksperimentell: Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD. |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navn:
|
|
Eksperimentell: Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD Dose
Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD. |
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)
Tidsramme: The first treatment 21-day cycle (Cycle 1)
|
Dose-limiting toxicities (DLTs) in Cycle 1 |
The first treatment 21-day cycle (Cycle 1)
|
|
Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)
Tidsramme: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1 |
Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
|
Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose
Tidsramme: Through study completion, approximately 1 year
|
Treatment-emergent adverse events |
Through study completion, approximately 1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Fase 2: For å vurdere progresjonsfri overlevelse ved RECIST versjon 1.1
Tidsramme: Dag 1 hver 2. syklus starter ved syklus 3 Dag 1 til studieavslutning, ca. 1 år (hver syklus er 21 dager)
|
Dag 1 hver 2. syklus starter ved syklus 3 Dag 1 til studieavslutning, ca. 1 år (hver syklus er 21 dager)
|
|
|
Fase 1: For å vurdere den foreløpige antitumoraktiviteten til silevertinib (BDTX-1535) ved objektiv respons som vurdert av RECIST versjon 1.1 (for pasienter med NSCLC) eller responsvurdering i nevro-onkologi (RANO) (for pasienter med GBM)
Tidsramme: Dag 1 hver 2 -syklus som starter på syklus 3 dag 1 for å studere fullføring, omtrent 1 år (hver syklus er 21 dager)
|
Dag 1 hver 2 -syklus som starter på syklus 3 dag 1 for å studere fullføring, omtrent 1 år (hver syklus er 21 dager)
|
|
|
Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)
Tidsramme: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Objective response rate (ORR) as assessed by Investigator using RECIST version 1.1 |
Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Black Diamond Therapeutics, Black Diamond Therapeutics
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- EGFR-hemmer
- hjernemetastaser
- EGFR L858R
- CNS-metastaser
- intrakraniell sykdom
- EGFR-endringer
- metastaser i sentralnervesystemet
- EGFR Exon 19 del
- egenresistens NSCLC EGFR
- ervervet resistens NSCLC EGFR
- uvanlige NSCLC EGFR-mutasjoner
- C797S ervervet resistens EGFR-mutasjon
- ikke-klassiske NSCLC EGFR-mutasjoner
- klassiske NSCLC EGFR-mutasjoner
- Andresteds EGFR-mutasjon
- EGFR PACC NSCLC-mutasjoner
- EGFR E709A/G/K/Q/V
- EGFR E709_T710delinsD/T
- EGFR G719A/C/D/R/S
- EGFR G724S
- EGFR L718Q/V
- EGFR L747S/P, L747_A750delinsP, L747_P753delinsS
Ytterligere relevante MeSH-vilkår
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Lungesykdommer
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Neoplasmer i nervesystemet
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Neoplasmer i sentralnervesystemet
- Lungeneoplasmer
- Karsinom, ikke-småcellet lunge
- Neoplasmer i hjernen
Andre studie-ID-numre
- BDTX-1535-101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .